- Conditions
- Covid19
- Interventions
- Infliximab, Abatacept, Remdesivir, cenicriviroc (closed to enrollment as of 3-Sep-2021)
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,971 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 54 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–18
of 18
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Nonalcoholic Steatohepatitis, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease
- Interventions
- Cenicriviroc
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 41
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
- Conditions
- Healthy
- Interventions
- Cenicriviroc, Pioglitazone
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Lakewood, Colorado
- Conditions
- AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex, Human Immunodeficiency Virus
- Interventions
- cenicriviroc
- Drug
- Lead sponsor
- University of Hawaii
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Healthy
- Interventions
- Cenicriviroc, Omeprazole, Famotidine
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
- Interventions
- Cenicriviroc 150 mg, Placebo
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Fort Sam Houston, Texas • San Antonio, Texas
- Conditions
- HIV-infection/AIDS
- Interventions
- Cenicriviroc, Dolutegravir, Midazolam
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- HIV-1-infection, Elevated Cardiovascular Risk
- Interventions
- CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 45 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 19
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 14 more
- Conditions
- Liver Insufficiency
- Interventions
- Cenicriviroc in mild liver impaired, Cenicriviroc in moderate liver impaired
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Fort Lauderdale, Florida
- Conditions
- HIV Infection
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Cenicriviroc 150 mg
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- La Jolla, California • Sacramento, California • San Francisco, California + 2 more
- Conditions
- Hepatic Impairment
- Interventions
- Cenicriviroc
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Tropifexor (LJN452), Cenicriviroc (CVC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 27
- States / cities
- Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 21 more
- Conditions
- COVID-19
- Interventions
- Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
- Drug · Biological
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Davis, California • Irvine, California + 30 more
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Placebo, Cenicriviroc
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 204
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 144 more
- Conditions
- HIV-1 Infection
- Interventions
- Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more
- Conditions
- Healthy
- Interventions
- Rosuvastatin, Atorvastatin, Simvastatin, Digoxin, Caffeine
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Cenicriviroc, Placebo
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 40
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more